Alector (ALEC) Competitors

$2.30 +0.15 (+6.98%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$2.31 +0.01 (+0.22%)

As of 05/14/2026 04:10 PM Eastern

ALEC vs. SEPN, AMPH, SVRA, CVAC, and MRVI

Should you buy Alector stock or one of its competitors? MarketBeat compares Alector with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alector include Septerna (SEPN), Amphastar Pharmaceuticals (AMPH), Savara (SVRA), CureVac (CVAC), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry.

How does Alector compare to Septerna?

Septerna (NASDAQ:SEPN) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

In the previous week, Alector had 4 more articles in the media than Septerna. MarketBeat recorded 11 mentions for Alector and 7 mentions for Septerna. Alector's average media sentiment score of 0.50 beat Septerna's score of 0.48 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Septerna	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alector	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Septerna has a beta of 2.21, indicating that its share price is 121% more volatile than the broader market. Comparatively, Alector has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Septerna presently has a consensus target price of $43.13, indicating a potential upside of 52.28%. Alector has a consensus target price of $3.63, indicating a potential upside of 57.61%. Given Alector's higher possible upside, analysts plainly believe Alector is more favorable than Septerna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Septerna	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Septerna has a net margin of -49.88% compared to Alector's net margin of -680.83%. Septerna's return on equity of -12.72% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Septerna	-49.88%	-12.72%	-8.87%
Alector	-680.83%	-295.17%	-40.95%

85.8% of Alector shares are held by institutional investors. 4.3% of Septerna shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Septerna has higher revenue and earnings than Alector. Septerna is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Septerna	$45.95M	27.78	-$48.88M	-$0.81	N/A
Alector	$21.05M	12.13	-$142.93M	-$1.19	N/A

Summary

Septerna beats Alector on 11 of the 17 factors compared between the two stocks.

How does Alector compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Amphastar Pharmaceuticals had 12 more articles in the media than Alector. MarketBeat recorded 23 mentions for Amphastar Pharmaceuticals and 11 mentions for Alector. Alector's average media sentiment score of 0.50 beat Amphastar Pharmaceuticals' score of 0.08 indicating that Alector is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	3 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alector	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amphastar Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Alector has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Amphastar Pharmaceuticals presently has a consensus target price of $24.50, indicating a potential upside of 41.62%. Alector has a consensus target price of $3.63, indicating a potential upside of 57.61%. Given Alector's stronger consensus rating and higher possible upside, analysts clearly believe Alector is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Alector's net margin of -680.83%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Alector	-680.83%	-295.17%	-40.95%

65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are held by insiders. Comparatively, 8.3% of Alector shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amphastar Pharmaceuticals has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.06	$98.09M	$1.66	10.42
Alector	$21.05M	12.13	-$142.93M	-$1.19	N/A

Summary

Amphastar Pharmaceuticals beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to Savara?

Alector (NASDAQ:ALEC) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, Alector had 5 more articles in the media than Savara. MarketBeat recorded 11 mentions for Alector and 6 mentions for Savara. Savara's average media sentiment score of 0.60 beat Alector's score of 0.50 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alector	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

85.8% of Alector shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 8.3% of Alector shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Savara has a net margin of 0.00% compared to Alector's net margin of -680.83%. Savara's return on equity of -87.19% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alector	-680.83%	-295.17%	-40.95%
Savara	N/A	-87.19%	-66.42%

Alector has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Savara has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Alector currently has a consensus target price of $3.63, suggesting a potential upside of 57.61%. Savara has a consensus target price of $9.13, suggesting a potential upside of 73.15%. Given Savara's stronger consensus rating and higher probable upside, analysts plainly believe Savara is more favorable than Alector.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13
Savara	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Savara has lower revenue, but higher earnings than Alector. Savara is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alector	$21.05M	12.13	-$142.93M	-$1.19	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Summary

Savara beats Alector on 10 of the 16 factors compared between the two stocks.

How does Alector compare to CureVac?

CureVac (NASDAQ:CVAC) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

CureVac has higher revenue and earnings than Alector. Alector is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Alector	$21.05M	12.13	-$142.93M	-$1.19	N/A

CureVac has a net margin of 199.92% compared to Alector's net margin of -680.83%. CureVac's return on equity of -23.03% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Alector	-680.83%	-295.17%	-40.95%

CureVac currently has a consensus price target of $6.83, indicating a potential upside of 46.64%. Alector has a consensus price target of $3.63, indicating a potential upside of 57.61%. Given Alector's stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

17.3% of CureVac shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Alector has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

In the previous week, Alector had 11 more articles in the media than CureVac. MarketBeat recorded 11 mentions for Alector and 0 mentions for CureVac. Alector's average media sentiment score of 0.50 beat CureVac's score of 0.00 indicating that Alector is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Alector	Positive

Summary

CureVac beats Alector on 9 of the 16 factors compared between the two stocks.

How does Alector compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Maravai LifeSciences had 2 more articles in the media than Alector. MarketBeat recorded 13 mentions for Maravai LifeSciences and 11 mentions for Alector. Maravai LifeSciences' average media sentiment score of 0.68 beat Alector's score of 0.50 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	3 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alector	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences has higher revenue and earnings than Alector. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	5.94	-$130.77M	-$0.71	N/A
Alector	$21.05M	12.13	-$142.93M	-$1.19	N/A

Maravai LifeSciences has a net margin of -51.07% compared to Alector's net margin of -680.83%. Maravai LifeSciences' return on equity of -17.87% beat Alector's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-51.07%	-17.87%	-9.08%
Alector	-680.83%	-295.17%	-40.95%

Maravai LifeSciences has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market. Comparatively, Alector has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Maravai LifeSciences currently has a consensus price target of $5.50, indicating a potential upside of 28.21%. Alector has a consensus price target of $3.63, indicating a potential upside of 57.61%. Given Alector's higher probable upside, analysts clearly believe Alector is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alector	2 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Maravai LifeSciences beats Alector on 9 of the 15 factors compared between the two stocks.

Get Alector News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALEC vs. The Competition

Export

Metric	Alector	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$238.70M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-1.93	18.47	20.66	25.63
Price / Sales	12.13	294.84	545.73	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	25.56	6.93	9.94	6.97
Net Income	-$142.93M	$24.11M	$3.55B	$333.62M
7 Day Performance	9.52%	5.89%	1.70%	1.09%
1 Month Performance	-10.85%	-0.91%	0.49%	3.08%
1 Year Performance	108.14%	74.58%	39.38%	35.68%

Alector Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALEC Alector	2.6805 of 5 stars	$2.30 +7.0%	$3.63 +57.6%	+115.0%	$238.70M	$21.05M	N/A	270	Analyst Revision Gap Up
SEPN Septerna	3.4138 of 5 stars	$23.87 -0.5%	$43.13 +80.7%	+178.7%	$1.08B	$45.95M	N/A	N/A	News Coverage Earnings Report Upcoming Earnings Analyst Forecast
AMPH Amphastar Pharmaceuticals	4.3852 of 5 stars	$19.00 -20.9%	$27.43 +44.4%	-25.8%	$1.07B	$719.89M	11.45	1,976	Analyst Forecast Gap Down High Trading Volume
SVRA Savara	2.5215 of 5 stars	$5.23 +1.4%	$9.13 +74.5%	+76.3%	$1.06B	N/A	N/A	20	Earnings Report
CVAC CureVac	N/A	$4.66 flat	$6.83 +46.6%	N/A	$1.05B	$70.74M	6.47	880

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALEC) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alector (ALEC) Competitors